– IRELAND, Dublin – Open Orphan plc (LON: ORPH) today announced the appointment of Mo Khan to its Board as an Independent Non-Executive Director with immediate effect.
Concurrently, Michael Meade is stepping down from the Board with immediate effect.
“We are delighted to announce the appointment of Mo Khan to the Board of Open Orphan. Mo has extensive CRO knowledge and experience in a fast growth business and will be an invaluable addition to the Company as we capitalise on our position as a leading European CRO and world leader in testing vaccines and therapeutics for infectious and respiratory diseases, as this market exponentially grows to an expected $250bn by 2025.” said Executive Chairman, Cathal Friel.
Mo will also Chair both the Audit and Risk and Nomination Committees.
About Yamin ‘Mo’ Khan
Mo is a business leader and customer-focused CRO executive with over 25 years of global clinical research experience across clinical operations, project management, business development, and executive management functions. He previously worked at Pharm-Olam International, a global CRO, from 2000-2019 across a variety of senior positions including EVP of Clinical Development and Global Director of Clinical Operations. Mo was a key leader in driving the expansion and growth of the company from a small niche European CRO to a global player with offices across all continents. Laterally, he led global business development at Pharm-Olam resulting in significant growth and a successful sale in 2017, delivering substantial returns to its shareholders. Before this, he worked at Innovex and Quintiles CRO.
Mo Khan commented: “I am delighted to join the Board of Open Orphan. I have been very impressed by the outstanding progress that Cathal Friel, the Board, and the team have made in such a short time. These are exciting times for Open Orphan and its subsidiaries in the light of their current full-service, high-quality offerings in conjunction with the increased interest in challenge studies. I look forward to working with them in the next stage of the evolution of Open Orphan.”
About Open Orphan
Open Orphan plc is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organizations.
Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic and its state-of-the-art 24-bedroom QMB clinic with its highly specialized on-site virology and immunology laboratory. Open Orphan has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing several other models. There has been an explosion in the growth of the infectious disease pharmaceuticals market, which is estimated to grow to more than $250bn by 2025. The Group is focused on refreshing its existing challenge models and develop new models, such as Malaria, to address the dramatic growth potential of the global infectious disease market.
Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion platform, this unique dataset includes clinical, immunological, virological, and digital biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end-users including big technology, wearables, pharma, and biotech companies.
Open Orphan’s Paris office has been providing biometry, data management, and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company’s Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), PK, and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third-party trial contracts.
For more information: https://www.openorphan.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
